Tumor Marker Kinetics as Prognosticators in Patients with Unresectable Gallbladder Adenocarcinoma Undergoing Palliative Chemotherapy

Jae Woo Lee1,2, Yong-Tae Kim1,2, Sang Hyub Lee1,2, Jun Hyuk Son1,2, Jin Woo Kang1,2, Ji Kon Ryu1,2, Dong Kee Jang3, Woo Hyun Paik4, and Ban Seok Lee5

1Department of Internal Medicine and Liver Research Institute, Seoul National University College of Medicine, 2Department of Internal Medicine, Seoul National University Hospital, Seoul, 3Department of Internal Medicine, Dongguk University Ilsan Medical Center, 4Department of Internal Medicine, Inje University Ilsan Paik Hospital, Inje University School of Medicine, Goyang, and 5Department of Internal Medicine, Gimhae Jungang Hospital, Gimhae, Korea

Background/Aims: To determine the prognostic value of carcinoembryonic antigen (CEA) and carbohydrate antigen (CA) 19-9 in gallbladder cancer (GBC) during palliative chemotherapy. Methods: One hundred and twenty-three patients with pathologically confirmed unresectable GBC were included. Differences in serum CEA and CA 19-9 levels before and after chemotherapy were measured. Receiver operating characteristic curve analysis, Kaplan-Meier analyses of CEA, CA 19-9, and combined changes were performed to assess the optimal cutoff values and survival rates. Results: Patients with decreased tumor markers had significantly better progression-free survival (PFS) and overall survival (OS) than patients with increased tumor markers. The pre- and postchemotherapy CA 19-9 ratio had the highest area-under-the-curve values for predicting 3-month PFS and 1-year OS. In the multivariate analysis, increases in serum CA 19-9 during palliative chemotherapy in patients with unresectable GBC was an independent prognosticator of poor PFS and OS, with hazard ratios of 2.20 (p=0.001) and 1.67 (p=0.020), respectively. Patients with increases >10-fold were likely to benefit from early imaging follow-up. Conclusions: CA 19-9 kinetics was a reliable prognosticator of PFS and OS in patients with unresectable GBC who underwent palliative chemotherapy. (Gut Liver 2018;12:102-110)

Key Words: Gallbladder neoplasms; CA-19-9 antigen; Carcinoembryonic antigen; Progression-free survival; Overall survival

INTRODUCTION

Gallbladder cancer (GBC) is the most common malignant tumor of the biliary tract. GBC is associated with a poor prognosis, with a 5-year overall survival (OS) rate of 18.5%, and only 20% of patients are eligible for resection at the time of diagnosis.1 Palliative chemotherapy has shown survival benefits,2 but the response rates are relatively low (17.1% to 36.6%).3 The median survival time of patients with GBC is 4.6 to 11.7 months.2,3 In biliary tract cancer, serum carbohydrate antigen (CA) 19-9 and carcinoembryonic antigen (CEA) have been associated with prognosis.4 Changes in these tumor markers during treatment were reported as prognosticators in pancreatic cancer5-8 and cholangiocarcinoma.9 For GBC, serum CEA and CA 19-9 are useful diagnostic10-13 and prognostic12,14-17 markers. However, previous studies employed spot measurements of CEA or CA 19-9, and studies evaluating the prognostic role of tumor marker kinetics in GBC have not been conducted.

The aim of the present study was to assess the prognostic values of serum CEA and CA 19-9 and their kinetics during palliative chemotherapy in patients with unresectable GBC.
MATERIALS AND METHODS

1. Patients and study design

A single-center retrospective study was conducted in patients with unresectable GBC, which was pathologically confirmed as adenocarcinoma between January 2005 and April 2015 at Seoul National University Hospital. Patients who underwent at least four cycles of palliative chemotherapy and who had baseline and postchemotherapy tumor marker records were included. Patients with other malignant tumors diagnosed previously, a history of systemic chemotherapy, or normal pre- and postchemotherapy tumor marker values were excluded (Fig. 1). The final analysis set included 123 patients.

All patients were followed up until 30 November 2015, and observations were censored at the time of death or loss to follow-up.

![Image of patient selection criteria]

Fig. 1. Patient selection criteria. GB, gallbladder; CA 19-9, carbohydrate antigen 19-9; CEA, carcinoembryonic antigen.

| Table 1. Baseline Characteristics of Eligible Patients |
|--------------------------------------------------------|
| Characteristic                                          | Value |
| Sex                                                     |       |
| Male                                                    | 62 (50.4) |
| Female                                                  | 61 (49.6) |
| Age, yr                                                 |       |
| ≥65                                                     | 57 (46.3) |
| <65                                                     | 66 (53.7) |
| Drinking history                                        |       |
| Yes                                                     | 31 (25.2) |
| No                                                      | 92 (74.8) |
| Smoking history                                         |       |
| Yes                                                     | 27 (22.0) |
| No                                                      | 96 (78.0) |
| Symptoms                                                |       |
| Yes                                                     | 113 (91.9) |
| No                                                      | 10 (8.1) |
| CCI (cancer score subtracted)                           |       |
| ≥4.0                                                    | 46 (37.4) |
| <4.0                                                    | 77 (62.6) |
| Total bilirubin, mg/dL                                  |       |
| ≥3.0                                                    | 32 (26.0) |
| <3.0                                                    | 91 (74.0) |

Data are presented as number (%) or median (range).

CCI, Charlson comorbidity index; CEA, carcinoembryonic antigen; CA 19-9, carbohydrate antigen 19-9; ECOG, Eastern Cooperative Oncology Group; COMB, combination.
2. Data collection

Patient characteristics such as age, sex, symptoms at admission, and comorbid disease status (Charlson comorbidity index score)\textsuperscript{18} were obtained. Variables in tumor characteristics including tumor location (fundus, body, and neck) and distant metastasis were collected. Serum CEA and CA 19-9 levels at baseline and postchemotherapy were evaluated. Baseline levels were measured within 3 days before chemotherapy initiation (CEA\textsubscript{pre} and CA 19-9\textsubscript{pre}). Postchemotherapy levels were measured within 3 days after the end of the second cycle of chemotherapy (CEA\textsubscript{post} and CA 19-9\textsubscript{post}). Serum CEA and CA 19-9 were measured using a commercially available immunoradiometric assays (CA 19-9: IZO

![Figure 2](https://example.com/figure2.png)

**Fig. 2.** Receiver operating characteristic (ROC) curve analysis of tumor marker kinetics as predictors of survival. (A) Progression-free survival. (B) Overall survival.

CEA, carcinoembryonic antigen; CA 19-9, carbohydrate antigen 19-9.

| Table 2. Sensitivity and Specificity for Predicting PFS and OS According to Serum Tumor Marker Changes after Chemotherapy |
|--------------------------------------------------|--------------------------------------------------|--------------------------------------------------|--------------------------------------------------|
|                        | CEA\textsubscript{change} | CA 19-9\textsubscript{change} | COMB\textsubscript{change} | CEA\textsubscript{change} | CA 19-9\textsubscript{change} | COMB\textsubscript{change} |
|------------------------|---------------------------|-------------------------------|---------------------------|---------------------------|-------------------------------|---------------------------|
| **Cutoff 0.5**          |                           |                               |                           |                           |                               |                           |
| Sensitivity, %          | 91.7*                     | 84.2*                         | 82.8*                     | 82.8*                     | 82.8*                         | 82.8*                     |
| Specificity, %          | 31.2*                     | 51.0*                         | 50.0*                     | 50.0*                     | 50.0*                         | 50.0*                     |
| <0.5                   | 5.93 ± 1.50\textsuperscript{1} | 6.00 ± 1.11\textsuperscript{1} | 5.93 ± 1.19\textsuperscript{1} | 10.20 ± 2.65\textsuperscript{1} | 11.40 ± 1.19\textsuperscript{1} | 11.40 ± 1.49\textsuperscript{1} |
| ≥0.5                   | 2.57 ± 0.63\textsuperscript{1} | 2.47 ± 0.29\textsuperscript{1} | 2.10 ± 0.41\textsuperscript{1} | 6.60 ± 0.39\textsuperscript{1} | 6.80 ± 0.23\textsuperscript{1} | 6.00 ± 0.61\textsuperscript{1} |
| p-value                | 0.067                     | <0.01                         | 0.009                     | 0.258                     | 0.001                         | 0.011                     |
| **Cutoff 1.0**          |                           |                               |                           |                           |                               |                           |
| Sensitivity, %          | 83.3*                     | 68.4*                         | 72.4*                     | 72.4*                     | 72.4*                         | 72.4*                     |
| Specificity, %          | 59.4*                     | 69.4*                         | 68.2*                     | 68.2*                     | 68.2*                         | 68.2*                     |
| <1.0                   | 5.87 ± 0.36\textsuperscript{1} | 5.60 ± 0.79\textsuperscript{1} | 5.30 ± 0.78\textsuperscript{1} | 11.40 ± 0.80\textsuperscript{1} | 9.60 ± 1.12\textsuperscript{1} | 8.93 ± 2.16\textsuperscript{1} |
| ≥1.0                   | 2.31 ± 0.36\textsuperscript{1} | 2.17 ± 0.27\textsuperscript{1} | 2.10 ± 0.23\textsuperscript{1} | 6.17 ± 0.50\textsuperscript{1} | 6.63 ± 0.43\textsuperscript{1} | 6.17 ± 0.52\textsuperscript{1} |
| p-value                | 0.002                     | <0.01                         | 0.002                     | 0.036                     | 0.008                         | 0.011                     |
| **Cutoff 2.0**          |                           |                               |                           |                           |                               |                           |
| Sensitivity, %          | 27.8*                     | 45.6*                         | 55.2*                     | 55.2*                     | 55.2*                         | 55.2*                     |
| Specificity, %          | 85.4*                     | 85.7*                         | 72.7*                     | 72.7*                     | 72.7*                         | 72.7*                     |
| <2.0                   | 4.27 ± 0.97\textsuperscript{1} | 4.40 ± 0.71\textsuperscript{1} | 4.37 ± 0.54\textsuperscript{1} | 7.47 ± 0.80\textsuperscript{1} | 8.80 ± 0.99\textsuperscript{1} | 7.87 ± 1.11\textsuperscript{1} |
| ≥2.0                   | 2.47 ± 0.53\textsuperscript{1} | 2.10 ± 0.40\textsuperscript{1} | 2.17 ± 0.49\textsuperscript{1} | 6.57 ± 0.25\textsuperscript{1} | 6.53 ± 0.54\textsuperscript{1} | 6.53 ± 0.47\textsuperscript{1} |
| p-value                | 0.397                     | 0.001                         | 0.039                     | 0.692                     | 0.021                         | 0.173                     |

Data are presented as mean±SD.

PFS, progression-free survival; OS, overall survival; CEA, carcinoembryonic antigen; CA 19-9, carbohydrate antigen 19-9; COMB, combination.

* Sensitivity plus specificity for 3-month PFS; † Sensitivity plus specificity for 1-year OS; ‡ Survival in months.
TOP® Institute of Isotopes Co., Ltd., Budapest, Hungary; CEA: RIAKEY®, Shinjin Medics Inc., Goyang, Korea). The initial total serum bilirubin levels and prothrombin times were also evaluated.

Data on progression-free survival (PFS) and OS were collected. Disease progression (PD) was assessed using abdominal computed tomography every two to four cycles of chemotherapy. PFS data was censored according to the date of loss to follow-up. The date of death was sourced from the records of the Korean Central Cancer Registry.

3. Statistical analyses

Tumor marker kinetics were defined as $\text{CEA}_{\text{change}} = \frac{\text{CEA}_{\text{post}}}{\text{CEA}_{\text{pre}}}$ and $\text{CA 19-9}_{\text{change}} = \frac{\text{CA 19-9}_{\text{post}}}{\text{CA 19-9}_{\text{pre}}}$. Combined tumor marker kinetics were defined as $\text{COMB}_{\text{change}} = \text{CEA}_{\text{change}} \times \text{CA 19-9}_{\text{change}}$. The median, and
first and third quadrant values of the kinetic parameters were calculated.

Receiver operating characteristic (ROC) curve analysis of CEA change, CA 19-9 change, and COMB change, was performed to assess 3-month PFS and 1-year OS rates. The cutoff value for the highest sum of sensitivity and specificity was used for further analyses. Kaplan-Meier analyses were performed for survival evaluation. The log-rank test was used to assess the relationships between tumor marker kinetic parameters and PFS or OS.

Univariate analysis with the log-rank test was conducted to compare survival using the cutoff values of the tumor marker kinetic parameters. Factors associated with survival in the univariate analysis with a p-value <0.10 were used in multivariate analysis. Cox regression analysis was performed to identify independent prognosticators.

Hazard ratios and 95% confidence intervals were calculated for each predictive factor. Two-sided p-values of <0.05 were considered statistically significant. All statistical analyses were performed with IBM SPSS Statistics version 22.0 (IBM Corp., Armonk, NY, USA).

Table 3. Correlations between Changes in CA 19-9 and Other Variables

| CA 19-9 | p-value |
|---------|---------|
| Decrease | Increase |
| Sex | | |
| Male | 26 | 30 | 0.560 |
| Female | 27 | 23 | |
| Age, yr | | |
| ≥65 | 27 | 23 | |
| <65 | 26 | 30 | 0.560 |
| Drinking | | |
| Yes | 16 | 12 | |
| No | 37 | 41 | 0.509 |
| Smoking | | |
| Yes | 11 | 13 | |
| No | 42 | 40 | 0.817 |
| CCI (cancer subtracted score) | | |
| ≥4.0 | 21 | 20 | |
| <4.0 | 32 | 33 | 1.000 |
| Symptoms | | |
| Yes | 47 | 50 | |
| No | 6 | 3 | 0.488 |
| Location | | |
| Fundus and body | 35 | 45 | |
| Neck | 18 | 8 | 0.041 |
| Distant metastasis | | |
| Yes | 31 | 39 | |
| No | 22 | 14 | 0.151 |
| Biliary drainage | | |
| Yes | 25 | 19 | |
| No | 28 | 34 | 0.324 |

Table 3. Continued

| CA 19-9 | p-value |
|---------|---------|
| Decrease | Increase |
| CEA, ng/mL | | |
| ≥4.0 | 25 | 27 | |
| <4.0 | 28 | 26 | 0.846 |
| CA 19-9, U/mL | | |
| ≥400 | 37 | 27 | |
| <400 | 16 | 26 | 0.073 |

CA 19-9, carbohydrate antigen 19-9; CCI, Charlson comorbidity index; CEA, carcinoembryonic antigen.
RESULTS

1. Patient demographics

Baseline patient characteristics are listed in Table 1. The median age was 64 years (range, 25 to 85 years). Thirty patients had stage IIIb disease, all of which had unresectable disease due to extensive liver invasion or regional lymph node metastasis. The majority of patients underwent gemcitabine plus cisplatin chemotherapy (61.0%) with a mean duration of 4.8 (±3.0) cycles. Other chemotherapy regimens included TS-1 plus cisplatin (15.5%) with a mean duration of 5.2 (±3.1) cycles, gemcitabine plus oxaliplatin (13.8%) with a mean duration of 5.9 (±3.7) cycles, gemcitabine plus TS-1 (4.1%), infusional 5-fluorouracil, doxorubicin, and mitomycin-C (1.6%), capecitabine alone (1.6%), and TS-1 alone (2.4%). The median Charlson comorbidity index was 8 (range, 3–13). The median serum CEA and CA 19-9 levels were 3.9 mg/L (range, 0.5 to 1,350 mg/L) and 413 U/mL (range, 1 to 145,000 U/mL), respectively. The median interval between diagnosis and chemotherapy was 16 days (range, 0 to 123 days). The median PFS and OS were 3.9 and 8.1 months, respectively.

2. Prognostic value of CEA change, CA 19-9 change, and COMB change

In the ROC analysis, the areas-under-the-curve of the CEA change, CA 19-9 change, and COMB change for predicting 3-month PFS were 0.727, 0.750, and 0.734, whereas those for 1-year OS were 0.623, 0.742, and 0.720, respectively (Fig. 2).

The relationships between tumor marker kinetics and survival are shown in Table 2. CA 19-9 change was significantly correlated with PFS and OS. However, CEA change was significantly correlated with PFS and OS only at the cutoff value of 1.0. The relationship between COMB change and PFS and OS was variable but significant at most values with the exception of a cutoff value of 2.0 for OS.

Survival curves according to tumor kinetic parameters using a cutoff value of 1.0 are shown in Fig. 3. The median PFS was 5.9 and 2.3 months in patients with a CEA change of <1 and ≥1, respectively (p=0.002). The median OS was 11.4 and 6.2 months in those with a CEA change of <1 and ≥1, respectively (p=0.036). The median PFS was 5.6 and 2.2 months in patients with a CA 19-9 change of <1 and ≥1, respectively (p<0.001). The median OS was 9.6 and 6.6 months in patients with a CA 19-9 change of <1 and ≥1, respectively (p=0.002).

Table 4. Prognosticators of PFS in Patients with Unresectable Gallbladder Cancer

|                      | Univariate | Multivariate |
|----------------------|------------|--------------|
|                      | No. PFS p-value | HR 95% CI p-value |
| Sex                  |             |              |
| Male                 | 62 2.7      | 0.095 0.81–1.23 0.317 |
| Female               | 61 4.8      |              |
| Age, yr              |             |              |
| ≥65                  | 57 3.9      |              |
| <65                  | 66 3.9      | 0.918        |
| Drinking             |             |              |
| Yes                  | 31 4.0      |              |
| No                   | 92 3.7      | 0.315        |
| Smoking              |             |              |
| Yes                  | 27 3.9      |              |
| No                   | 96 4.0      | 0.839        |
| Symptom              |             |              |
| Yes                  | 113 3.9     |              |
| No                   | 10 2.6      | 0.826        |
| Performance status (ECOG) |   |              |
| 0 or 1               | 101 4.0     |              |
| 2                    | 22 3.2      | 0.505        |
| Location             |             |              |
| Fundus and body      | 95 3.4      |              |
| Neck                 | 28 4.5      | 0.076 0.79–1.38 0.410 |
| Distant metastasis   |             |              |
| Yes                  | 78 2.7      |              |
| No                   | 45 5.7      | 0.018 1.45–2.29 0.115 |
| Biliary drainage     |             |              |
| Yes                  | 51 3.4      |              |
| No                   | 72 4.8      | 0.171        |
| Total bilirubin, mg/dL |           |              |
| ≥3.0                 | 32 3.4      |              |
| <3.0                 | 91 4.3      | 0.336        |

Table 4. Continued

|                      | Univariate | Multivariate |
|----------------------|------------|--------------|
|                      | No. PFS p-value | HR 95% CI p-value |
| CEA, ng/mL           |             |              |
| ≥4.0                 | 66 3.2      |              |
| <4.0                 | 57 4.4      | 0.066 1.44–2.29 0.112 |
| CA 19-9, U/mL        |             |              |
| ≥400                 | 68 3.9      |              |
| <400                 | 55 3.9      | 0.328        |
| Chemotherapy         |             |              |
| GP                   | 75 4.0      |              |
| Others               | 48 3.4      | 0.851        |
| Interval between diagnosis and treatment, day | | |
| ≤15                  | 59 4.0      |              |
| >15                  | 64 3.9      | 0.433        |
| CA 19-9 change       |             |              |
| ≥1.0                 | 53 5.6      |              |
| <1.0                 | 53 2.2      | <0.001 2.20–3.47 0.001 |

PFS, progression-free survival; HR, hazard ratio; CI, confidence interval; ECOG, Eastern Cooperative Oncology Group; CEA, carcinoembryonic antigen; CA 19-9, carbohydrate antigen 19-9; GP, gemcitabine plus cisplatin.
and ≥1, respectively (p=0.008). The median PFS was 5.3 and 2.1 months in those with a COMB change of <1 and ≥1 (p=0.002). The median OS was 8.9 and 6.2 months in those with a COMB change of <1 and ≥1, respectively (p=0.011).

CA 19-9 change was the most valuable prognostic marker. Kaplan-Meier analyses according to CA 19-9 change cutoff value of 0.4, 1.0, and 2.0 (which represent the first quadrant, median, and third quadrant) are shown in Fig. 4. Patients with a CA 19-9 change <0.4 had significantly better survival compared to those with greater changes. The linearity of the PFS and OS in were statistically significant (both p<0.001). Because CA 19-9 change was the most valuable prognosticator, we used CA 19-9 change as a marker in further analyses.

3. CA 19-9 change as a predictor of response to chemotherapy

Responses after four-cycle (rather than 3-month due to the variety of chemotherapy regimen) of chemotherapy were assessed according to the modified Response Evaluation Criteria in Solid Tumors (version 1.1). Sixteen patients (13.0%) had a partial response, 41 (33.3%) had stable disease, and 66 (53.7%) showed PD. A high CA 19-9 change was correlated with PD (p=0.001), but a low CA 19-9 change was not associated with partial response (p=0.500). Three patients with a CA 19-9 change ≥10.0 showed PD after four-cycle of chemotherapy, and 20 patients with CA 19-9 change >3.0, 17 (85%) of whom underwent four-cycle of chemotherapy showed PD.

4. Prognostic value of CA 19-9 change associated with PFS

The correlations of CA 19-9 change with other baseline variables were analyzed, but there were no significant correlations (Table 3). Univariate analysis revealed that male sex (p=0.095), a primary mass located in the gallbladder neck (p=0.076), positive distant metastasis (p=0.018), CEA ≥4.0 ng/mL at diagnosis (p=0.045), and CA 19-9 change ≥1.0 (p=0.001) had a p-value of <0.10 for PFS. However, CA 19-9 change ≥1.0 alone was an independent prognostic factor of PFS (p=0.001) (Table 4).

5. Prognostic value of CA 19-9 change associated with OS

Univariate analyses revealed that male sex (p=0.058), an Eastern Cooperative Oncology Group performance score of 2 (p=0.050), distant metastasis (p=0.072), CEA ≥4.0 ng/mL (p=0.001), CA 19-9 ≥400 U/mL (p=0.007), and CA 19-9 change ≥1.0 (p=0.008) had a p-value of <0.10. Multivariate Cox regression analysis showed that baseline CEA ≥4.0 ng/mL, baseline CA 19-9 ≥400 U/mL, and CA 19-9 change ≥1.0 were independent prognosticators of OS (p=0.018, p=0.022, and p=0.020, respectively) (Table 5).

6. Effect of total serum bilirubin on CA 19-9 levels

The correlation between serum CA 19-9 and serum total bilirubin level, and that between CA 19-9 change and serum total bilirubin were not significant (p=0.155 and 0.845, respectively). We

Table 5. Prognosticators of OS in Patients with Unresectable Gallbladder Cancer

|                | Univariate | Multivariate |
|----------------|------------|--------------|
|                | No. | OS | p-value | HR | 95% CI | p-value |
| Sex            |     |    |         |    |        |         |
| Male           | 62  | 7.0|         |    |        |         |
| Female         | 61  | 8.8| 0.058   | 0.81| 0.53–1.23| 0.320   |
| Age, yr        |     |    |         |    |        |         |
| ≥65            | 57  | 6.9|         |    |        |         |
| <65            | 66  | 9.5| 0.130   |    |        |         |
| Smoking        |     |    |         |    |        |         |
| Yes            | 27  | 8.3|         |    |        |         |
| No             | 96  | 7.8| 0.419   |    |        |         |
| Symptoms       |     |    |         |    |        |         |
| Yes            | 113 | 7.9|         |    |        |         |
| No             | 10  | 8.9| 0.274   |    |        |         |
| Performance status (ECOG) |     |    |         |    |        |         |
| 0 or 1         | 101 | 8.3|         |    |        |         |
| 2              | 22  | 6.6| 0.050   | 1.15| 0.69–1.93| 0.592   |
| Location       |     |    |         |    |        |         |
| Fundus and body | 95 | 7.8|         |    |        |         |
| Neck           | 28  | 9.5| 0.104   |    |        |         |
| Distant metastasis |  |    |         |    |        |         |
| Yes            | 78  | 6.8|         |    |        |         |
| No             | 45  | 9.6| 0.072   | 1.35| 0.87–2.11| 0.186   |
| Biliary drainage |    |    |         |    |        |         |
| Yes            | 51  | 7.0|         |    |        |         |
| No             | 72  | 8.3| 0.669   |    |        |         |
| Total bilirubin, mg/dL |   |    |         |    |        |         |
| ≥3.0           | 32  | 7.0|         |    |        |         |
| <3.0           | 91  | 8.1| 0.763   |    |        |         |
| CEA, ng/mL     |     |    |         |    |        |         |
| ≥4.0           | 66  | 6.8|         |    |        |         |
| <4.0           | 57  | 9.6| 0.001   | 1.76| 1.10–2.80| 0.018   |
| CA 19-9, U/mL  |     |    |         |    |        |         |
| ≥400           | 68  | 7.0|         |    |        |         |
| <400           | 55  | 9.6| 0.007   | 1.74| 1.08–2.08| 0.003   |
| Chemotherapy   |     |    |         |    |        |         |
| GP             | 75  | 7.8|         |    |        |         |
| Others         | 48  | 8.3| 0.250   |    |        |         |
| CA 19-9 change |     |    |         |    |        |         |
| ≥1.0           | 53  | 6.6|         |    |        |         |
| <1.0           | 53  | 9.6| 0.008   | 1.67| 1.08–2.58| 0.020   |

OS, overall survival; HR, hazard ratio; CI, confidence interval; ECOG, Eastern Cooperative Oncology Group; CEA, carcinoembryonic antigen; CA 19-9, carbohydrate antigen 19-9; GP, gemcitabine plus cisplatin.
did a subgroup analysis which divided the subjects according to serum total bilirubin levels, and 29 out of 106 patients had a serum total bilirubin level >3.0 mg/dL (Table 6). The median PFS was 4.0 and 2.7 months in patients with a CA 19-9 change of <1 and ≥1, respectively [p=0.296]. The median OS was 7.1 and 6.7 months in patients with a CA 19-9 change of <1 and ≥1, respectively [p=0.955].

**DISCUSSION**

In this retrospective study, we aimed to assess the prognostic value of serum tumor marker kinetics after chemotherapy in patients with unresectable GBC. The results revealed that tumor marker changes after first two cycles of chemotherapy were independent prognosticators of survival. Serum CEA, serum CA 19-9, or a combination of the two were valuable prognosticators; however, among them, CA 19-9 kinetics was the most valuable prognosticator of survival. In addition, the serum CA 19-9 level after two cycles of chemotherapy was a valuable predictor of PD after four cycles of chemotherapy. Therefore, we suggest that patients with >10-fold increase in serum CA 19-9 after two cycles of chemotherapy should be considered as having PD, and patients with >3-fold increase in serum CA 19-9 should be considered for early imaging studies.

Multivariate analyses in previous studies of patients with GBC that utilized specific cutoff values of spot serum CA 19-9 did not identify serum CA 19-9 as an independent prognosticator. However, among them, CA 19-9 kinetics was the most valuable prognosticator of survival. In addition, the serum CA 19-9 level after two cycles of chemotherapy was a valuable predictor of PD after four cycles of chemotherapy. Therefore, we suggest that patients with >10-fold increase in serum CA 19-9 after two cycles of chemotherapy should be considered as having PD, and patients with >3-fold increase in serum CA 19-9 should be considered for early imaging studies.

Multivariate analyses in previous studies of patients with GBC that utilized specific cutoff values of spot serum CA 19-9 did not identify serum CA 19-9 as an independent prognosticator. However, among them, CA 19-9 kinetics was the most valuable prognosticator of survival. In addition, the serum CA 19-9 level after two cycles of chemotherapy was a valuable predictor of PD after four cycles of chemotherapy. Therefore, we suggest that patients with >10-fold increase in serum CA 19-9 after two cycles of chemotherapy should be considered as having PD, and patients with >3-fold increase in serum CA 19-9 should be considered for early imaging studies.

There is no universal agreement on how to adjust serum total bilirubin levels between GBC cases. Although the serum CA 19-9 levels vary between patients and may not represent tumor burden, the relative value of CA 19-9 in a single patient may be reflective of the tumor burden, regardless of the absolute CA 19-9 level. The present study showed that the relative change in CA 19-9 did not correlate with spot serum CA 19-9 measurements, and that the relative change was an independent prognosticator, similar to previous findings in pancreatic cancer and cholangiocarcinoma.

Yu et al. focused on the change of serum CA 19-9 and CEA after resection of GBC. They showed that increased CA 19-9 and CEA after GBC resection were independent prognosticators of poor survival. Combined with postoperative pathology, which is the most important prognosticator, they classified postsurgical patients into different prognostic groups, which aided further decision making. Unlike patients with resectable GBC, patients with unresectable GBC undergo palliative chemotherapy and exhibit variable tumor responses, a valid assessment of such responses is critical in further decision making. The present study focused on the relationship between chemotherapy response and tumor marker changes, and identified criteria for early imaging follow-up or chemotherapy discontinuation based on these changes.

We excluded subjects with normal pre- and postchemotherapy tumor markers in this study and this may create some degree of selection bias. However, excluding such subjects does not facilitate any favorable tendency in the conclusion of this study. On the other hand, we could not conclude some issues regarding chemotherapy response due to the insufficient number of subjects. Despite tumor marker kinetics significantly correlated with progressive disease, we could not draw a conclusion correlating tumor marker kinetics with partial or complete response. Only 16 patients showed partial response to chemotherapy and there were no patients with complete response. Studies with a larger number of subjects are warranted to reach a conclusion.

High baseline serum total bilirubin is correlated with high baseline serum CA 19-9 level, and could therefore influence CA 19-9 change. There is no universal agreement on how to adjust the serum CA 19-9 level. Kim et al. suggested a formula correcting the effect of serum total bilirubin on serum CA 19-9 level, which divides serum CA 19-9 level with serum total bilirubin level. However, the serum total bilirubin threshold 2.0 mg/dL makes this formula inadequate to this study due to the measurable nature of tumor marker changes. Instead, we did a subgroup analysis, and 29 of 106 patients had a serum total bilirubin level >3.0 mg/dL (Table 6). High baseline serum bilirubin (>3.0 mg/dL) tended to be associated with improved survival in patients with a lower CA 19-9 change, although the association did not reach significance, most likely because of the small number of patients. Therefore, the influence of combined total bilirubin and serum CA 19-9 changes should be evaluated in further studies with a larger number of patients.

In conclusion, CA 19-9 kinetics is a valuable prognosticator of patient survival and treatment response during chemotherapy for unresectable GBC.

### Table 6. Survival Analysis of High- and Low-Serum Bilirubin Subgroups

| Bilirubin ≥3 mg/dL | CA 19-9 change <1 [n=18] | CA 19-9 change ≥1 [n=11] | p-value | CA 19-9 change <1 [n=35] | CA 19-9 change ≥1 [n=42] | p-value |
|-------------------|--------------------------|--------------------------|---------|--------------------------|--------------------------|---------|
| PFS, median, mo   | 4                        | 2.7                      | 0.296   | 5.9                      | 2.2                      | <0.001  |
| OS, median, mo    | 7.1                      | 6.7                      | 0.955   | 10.2                     | 6.6                      | <0.001  |

CA 19-9, carbohydrate antigen 19-9; PFS, progression-free survival; OS, overall survival.
CONFLICTS OF INTEREST

No potential conflict of interest relevant to this article was reported.

REFERENCES

1. Howlader N, Noone AM, Krapcho M, et al. SEER cancer statistics review, 1975-2013. Bethesda: National Cancer Institute, 2015.
2. Sharma A, Dwary AD, Mohanti BK, et al. Best supportive care compared with chemotherapy for unresectable gall bladder cancer: a randomized controlled study. J Clin Oncol 2010;28:4581-4586.
3. Park JO, Oh DY, Hsu C, et al. Gemcitabine plus cisplatin for advanced biliary tract cancer: a systematic review. Cancer Res Treat 2015;47:343-361.
4. Grunnet M, Mau-Sørensen M. Serum tumor markers in bile duct cancer: a review. Biomarkers 2014;19:437-443.
5. Vainshtein JM, Schipper M, Zalupski MM, et al. Prognostic significance of carbohydrate antigen 19-9 in unresectable locally advanced pancreatic cancer treated with dose-escalated intensity modulated radiation therapy and concurrent full-dose gemcitabine: analysis of a prospective phase 1/2 dose escalation study. Int J Radiat Oncol Biol Phys 2013;86:96-101.
6. Ziske C, Schlie C, Gorschlüter M, et al. Prognostic value of CA 19-9 levels in patients with inoperable adenocarcinoma of the pancreas treated with gemcitabine. Br J Cancer 2003;89:1413-1417.
7. Haas M, Heinemann V, Kullmann F, et al. Prognostic value of CA 19-9, CEA, CRP, LDH and bilirubin levels in locally advanced and metastatic pancreatic cancer: results from a multicenter, pooled analysis of patients receiving palliative chemotherapy. J Cancer Res Clin Oncol 2013;139:681-689.
8. Ko AH, Hwang J, Venook AP, Abbruzzese JL, Bergsland EK, Tempero MA. Serum CA19-9 response as a surrogate for clinical outcome in patients receiving fixed-dose rate gemcitabine for advanced pancreatic cancer. Br J Cancer 2005;93:195-199.
9. Lee BS, Lee SH, Son JH, et al. Prognostic value of CA 19-9 kinetics during gemcitabine-based chemotherapy in patients with advanced cholangiocarcinoma. J Gastroenterol Hepatol 2016;31:493-500.
10. Shukla VK, Gurubachan, Sharma D, Dixit VK, Usha. Diagnostic value of serum CA242, CA 19-9, CA 15-3 and CA 125 in patients with carcinoma of the gallbladder. Trop Gastroenterol 2006;27:160-165.
11. Rana S, Dutta U, Kochhar R, et al. Evaluation of CA 242 as a tumor marker in gallbladder cancer. J Gastrointest Cancer 2012;43:267-271.
12. Wang YF, Feng FL, Zhao XH, et al. Combined detection tumor markers for diagnosis and prognosis of gallbladder cancer. World J Gastroenterol 2014;20:4085-4092.
13. Huang L, Chen W, Liang P, et al. Serum CYFRA 21-1 in biliary tract cancers: a reliable biomarker for gallbladder carcinoma and intrabhepatic cholangiocarcinoma. Dig Dis Sci 2015;60:1273-1283.
14. Yu T, Yu H, Cai X. Preoperative prediction of survival in resectable gallbladder cancer by a combined utilization of CA 19-9 and carcinoembryonic antigen. Chin Med J (Engl) 2014;127:2299-2303.
15. Jeong Y, Park JH, Lee YJ, et al. Postoperative radiotherapy for gallbladder cancer. Anticancer Res 2014;34:5621-5629.
16. Noshiro H, Chijiwa K, Yamaguchi K, Shimizu S, Sugitani A, Tanaka M. Factors affecting surgical outcome for gallbladder carcinoma. Hepatogastroenterology 2003;50:939-944.
17. Shukla PJ, Neve R, Barreto SG, et al. A new scoring system for gallbladder cancer (aiding treatment algorithm): an analysis of 335 patients. Ann Surg Oncol 2008;15:3132-3137.
18. Fernández-Ruiz M, Guerra-Vales JM, Colina-Ruizdelgado F. Co-morbidity negatively influences prognosis in patients with extrahepatic cholangiocarcinoma. World J Gastroenterol 2009;15:5279-5286.
19. Sun XN, Cao WG, Wang X, et al. Prognostic impact of vascular endothelial growth factor-A expression in resected gallbladder carcinoma. Tumour Biol 2011;32:1183-1190.
20. Kwon YJ, Lee KG. Is T-stage the only significant factor determining the extent of surgery for gallbladder cancer? Hepatogastroenterology 2014;61:304-306.
21. Chakravarty KD, Yeh CN, Jan YY, Chen MF. Factors influencing long-term survival in patients with T3 gallbladder adenocarcinoma. Digestion 2009;79:151-157.
22. Ong SL, Sachdeva A, Garcea G, et al. Elevation of carbohydrate antigen 19.9 in benign hepatobiliary conditions and its correlation with serum bilirubin concentration. Dig Dis Sci 2008;53:3213-3217.
23. Kim YC, Kim HJ, Park JH, et al. Can preoperative CA19-9 and CEA levels predict the resectability of patients with pancreatic adenocarcinoma? J Gastroenterol Hepatol 2009;24:1869-1875.